Literature DB >> 25148094

Long-term survival and quality of life in dogs with clinical signs associated with a congenital portosystemic shunt after surgical or medical treatment.

Stephen N Greenhalgh1, Jenny A Reeve, Thurid Johnstone, Mark R Goodfellow, Mark D Dunning, Emma J O'Neill, Ed J Hall, Penny J Watson, Nick D Jeffery.   

Abstract

OBJECTIVE: To compare long-term survival and quality of life data in dogs with clinical signs associated with a congenital portosystemic shunt (CPSS) that underwent medical or surgical treatment.
DESIGN: Prospective cohort study. ANIMALS: 124 client-owned dogs with CPSS. PROCEDURES: Dogs received medical or surgical treatment without regard to signalment, clinical signs, or clinicopathologic results. Survival data were analyzed with a Cox regression model. Quality of life information, obtained from owner questionnaires, included frequency of CPSS-associated clinical signs (from which a clinical score was derived), whether owners considered their dog normal, and (for surgically treated dogs) any ongoing medical treatment for CPSS. A Mann-Whitney U test was used to compare mean clinical score data between surgically and medically managed dogs during predetermined follow-up intervals.
RESULTS: 97 dogs underwent surgical treatment; 27 were managed medically. Median follow-up time for all dogs was 1,936 days. Forty-five dogs (24 medically managed and 21 surgically managed) died or were euthanized during the follow-up period. Survival rate was significantly improved in dogs that underwent surgical treatment (hazard ratio, 8.11; 95% CI, 4.20 to 15.66) than in those treated medically for CPSS. Neither age at diagnosis nor shunt type affected survival rate. Frequency of clinical signs was lower in surgically versus medically managed dogs for all follow-up intervals, with a significant difference between groups at 4 to 7 years after study entry. CONCLUSIONS AND CLINICAL RELEVANCE: Surgical treatment of CPSS in dogs resulted in significantly improved survival rate and lower frequency of ongoing clinical signs, compared with medical management. Age at diagnosis did not affect survival rate and should not influence treatment choice.

Entities:  

Mesh:

Year:  2014        PMID: 25148094     DOI: 10.2460/javma.245.5.527

Source DB:  PubMed          Journal:  J Am Vet Med Assoc        ISSN: 0003-1488            Impact factor:   1.936


  11 in total

1.  Health-related quality of life in dogs treated with electrochemotherapy and/or interleukin-12 gene electrotransfer.

Authors:  Nina Milevoj; Natasa Tozon; Sabina Licen; Ursa Lampreht Tratar; Gregor Sersa; Maja Cemazar
Journal:  Vet Med Sci       Date:  2020-01-07

2.  Efficacy of orally administered sodium benzoate and sodium phenylbutyrate in dogs with congenital portosystemic shunts.

Authors:  Giora van Straten; Diewke van Dalen; Sietske J Mesu; Jan Rothuizen; Erik Teske; Bart Spee; Robert P Favier; Ingeborg M van Geijlswijk
Journal:  J Vet Intern Med       Date:  2019-03-27       Impact factor: 3.333

Review 3.  Treatment of congenital extrahepatic portosystemic shunts in dogs: A systematic review and meta-analysis.

Authors:  Gonçalo Serrano; Marios Charalambous; Nausikaa Devriendt; Hilde de Rooster; Femke Mortier; Dominique Paepe
Journal:  J Vet Intern Med       Date:  2019-08-31       Impact factor: 3.333

4.  Astrocyte lesions in cerebral cortex and cerebellum of dogs with congenital ortosystemic shunting.

Authors:  Alun Williams; Adam Gow; Scott Kilpatrick; Mickey Tivers; Vicky Lipscomb; Ken Smith; Michael Oliver Day; Nick Jeffery; Richard John Mellanby
Journal:  J Vet Sci       Date:  2020-05       Impact factor: 1.672

5.  Evaluation of serum lidocaine/monoethylglycylxylidide concentration to assess shunt closure in dogs with extrahepatic portosystemic shunts.

Authors:  Nausikaa Devriendt; Gonçalo Serrano; Siska Croubels; Emmelie Stock; Eva Vandermeulen; Dominique Paepe; Jennifer von Luckner; Hilde de Rooster
Journal:  J Vet Intern Med       Date:  2021-01-12       Impact factor: 3.175

6.  Comparison of diet, lactulose, and metronidazole combinations in the control of pre-surgical clinical signs in dogs with congenital extrahepatic portosystemic shunts.

Authors:  Goncalo Serrano; Nausikaa Devriendt; Hilde de Rooster; Dominique Paepe
Journal:  J Vet Intern Med       Date:  2022-05-28       Impact factor: 3.175

7.  Laparoscopic attenuation of a congenital extrahepatic portosystemic shunt in a dog-a thin-film banding for splenophrenic shunt: A case report.

Authors:  Jiyoung Park; Kwangsik Jang; Hyun Min Jo; Se Eun Kim
Journal:  Front Vet Sci       Date:  2022-09-26

8.  Genome-wide based model predicting recovery from portosystemic shunting after liver shunt attenuation in dogs.

Authors:  Lindsay Van den Bossche; Frank G van Steenbeek; Maarten F Weber; Bart Spee; Louis C Penning; Freek J van Sluijs; Flin Zomerdijk; Marian J A Groot Koerkamp; Jan Rothuizen; Iwan A Burgener; Anne Kummeling
Journal:  J Vet Intern Med       Date:  2018-05-17       Impact factor: 3.333

9.  Outcome of non-surgical dietary treatment with or without lactulose in dogs with congenital portosystemic shunts.

Authors:  Robert P Favier; Eline de Graaf; Ronald J Corbee; Anne Kummeling
Journal:  Vet Q       Date:  2020-12       Impact factor: 3.320

10.  Resolution of Severe Neurologic Signs Following Intravenous Lipid Emulsion Therapy in a Young Dog With a Portosystemic Shunt: Case Report.

Authors:  Amanda M Spillane; Jenica L Haraschak; Maureen A McMichael
Journal:  Front Vet Sci       Date:  2021-12-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.